What are we learning from the cancer genome?

Eric A. Collisson, Raymond J. Cho, Joe Gray

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Massively parallel approaches to nucleic acid sequencing have matured from proof-of-concept to commercial products during the past 5 years. These technologies are now widely accessible, increasingly affordable, and have already exerted a transformative influence on the study of human cancer. Here, we review new features of cancer genomes that are being revealed by large-scale applications of these technologies. We focus on those insights most likely to affect future clinical practice. Foremost among these lessons, we summarize the formidable genetic heterogeneity within given cancer types that is appreciable with higher resolution profiling and larger sample sets. We discuss the inherent challenges of defining driving genomic events in a given cancer genome amidst thousands of other somatic events. Finally, we explore the organizational, regulatory and societal challenges impeding precision cancer medicine based on genomic profiling from assuming its place as standard-of-care.

Original languageEnglish (US)
Pages (from-to)621-630
Number of pages10
JournalNature Reviews Clinical Oncology
Volume9
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

Learning
Genome
Neoplasms
Technology
Precision Medicine
Genetic Heterogeneity
Standard of Care
Nucleic Acids

ASJC Scopus subject areas

  • Oncology

Cite this

What are we learning from the cancer genome? / Collisson, Eric A.; Cho, Raymond J.; Gray, Joe.

In: Nature Reviews Clinical Oncology, Vol. 9, No. 11, 11.2012, p. 621-630.

Research output: Contribution to journalArticle

Collisson, Eric A. ; Cho, Raymond J. ; Gray, Joe. / What are we learning from the cancer genome?. In: Nature Reviews Clinical Oncology. 2012 ; Vol. 9, No. 11. pp. 621-630.
@article{e4bd70b9a5ec4a3b9520b56005e05f10,
title = "What are we learning from the cancer genome?",
abstract = "Massively parallel approaches to nucleic acid sequencing have matured from proof-of-concept to commercial products during the past 5 years. These technologies are now widely accessible, increasingly affordable, and have already exerted a transformative influence on the study of human cancer. Here, we review new features of cancer genomes that are being revealed by large-scale applications of these technologies. We focus on those insights most likely to affect future clinical practice. Foremost among these lessons, we summarize the formidable genetic heterogeneity within given cancer types that is appreciable with higher resolution profiling and larger sample sets. We discuss the inherent challenges of defining driving genomic events in a given cancer genome amidst thousands of other somatic events. Finally, we explore the organizational, regulatory and societal challenges impeding precision cancer medicine based on genomic profiling from assuming its place as standard-of-care.",
author = "Collisson, {Eric A.} and Cho, {Raymond J.} and Joe Gray",
year = "2012",
month = "11",
doi = "10.1038/nrclinonc.2012.159",
language = "English (US)",
volume = "9",
pages = "621--630",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - What are we learning from the cancer genome?

AU - Collisson, Eric A.

AU - Cho, Raymond J.

AU - Gray, Joe

PY - 2012/11

Y1 - 2012/11

N2 - Massively parallel approaches to nucleic acid sequencing have matured from proof-of-concept to commercial products during the past 5 years. These technologies are now widely accessible, increasingly affordable, and have already exerted a transformative influence on the study of human cancer. Here, we review new features of cancer genomes that are being revealed by large-scale applications of these technologies. We focus on those insights most likely to affect future clinical practice. Foremost among these lessons, we summarize the formidable genetic heterogeneity within given cancer types that is appreciable with higher resolution profiling and larger sample sets. We discuss the inherent challenges of defining driving genomic events in a given cancer genome amidst thousands of other somatic events. Finally, we explore the organizational, regulatory and societal challenges impeding precision cancer medicine based on genomic profiling from assuming its place as standard-of-care.

AB - Massively parallel approaches to nucleic acid sequencing have matured from proof-of-concept to commercial products during the past 5 years. These technologies are now widely accessible, increasingly affordable, and have already exerted a transformative influence on the study of human cancer. Here, we review new features of cancer genomes that are being revealed by large-scale applications of these technologies. We focus on those insights most likely to affect future clinical practice. Foremost among these lessons, we summarize the formidable genetic heterogeneity within given cancer types that is appreciable with higher resolution profiling and larger sample sets. We discuss the inherent challenges of defining driving genomic events in a given cancer genome amidst thousands of other somatic events. Finally, we explore the organizational, regulatory and societal challenges impeding precision cancer medicine based on genomic profiling from assuming its place as standard-of-care.

UR - http://www.scopus.com/inward/record.url?scp=84868201489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868201489&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2012.159

DO - 10.1038/nrclinonc.2012.159

M3 - Article

VL - 9

SP - 621

EP - 630

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 11

ER -